Infante Pina D, Redecillas Ferreiro S, Torrent Vernetta A, Segarra Cantón O, Maldonado Smith M, Gartner Tizziano L, Hidalgo Albert E
Unidad de Gastroenterología, Hepatología y Soporte Nutricional, Hospital Materno-Infantil Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, España.
An Pediatr (Barc). 2008 Dec;69(6):501-5. doi: 10.1016/s1695-4033(08)75231-7.
In some cases, cystic fibrosis may include intestinal inflammation and bacterial overgrowth. Probiotics are considered as immunomodulatory, anti-inflammatory and microbiotic regulator substances. The aim of our study is to determine the prevalence of bacterial overgrowth in cystic fibrosis patients and try to improve the intestinal function with the administration of probiotics.
We examined 20 patients with cystic fibrosis (mean age 10.33, range 5 to 17 years). The expired hydrogen test with a 2 g/kg of 20% dextrose overload was performed on 10 patients. After the test, Lactobacillus rhamnosus LGG 10(11) CFU was administered twice daily for four weeks. Faecal near infrared spectroscopy (FENIR) of water, fat, nitrogen and sugar content in faeces was performed before and after probiotics administration.
Five patients (50%) showed bacterial overgrowth. We obtained a positive correlation between the hydrogen test and steatorrhea (R = 0.57) and sugar in faeces (R = 0.52). The FENIR results pre-treatment vs post-treatment were: fat 6.2 g +/- 3.3 g vs. 4.9 g +/- 2.1 g (p < 0.05), sugar 6.7 +/- g 3.6 g vs. 5 g +/- 2.6 g (p < 0.05) and nitrogen 0.87 g +/- 0.27 g vs. 0.91 g +/- 0.14 g (NS) respectively. Thirteen patients (81.25%) had improved stool appearance and intestinal comfort and nine (56.25%) decreased the number of daily stools.
Probiotics improved not only clinical but also biochemical intestinal function in cystic fibrosis patients. These could be given as a regular treatment in this type of patients and in those with bacterial overgrowth.
在某些情况下，囊性纤维化可能包括肠道炎症和细菌过度生长。益生菌被认为是免疫调节、抗炎和微生物调节剂物质。我们研究的目的是确定囊性纤维化患者中细菌过度生长的患病率，并尝试通过给予益生菌来改善肠道功能。
我们检查了20例囊性纤维化患者（平均年龄10.33岁，范围5至17岁）。对10例患者进行了2 g/kg 20%葡萄糖负荷的呼气氢试验。试验后，每天两次给予鼠李糖乳杆菌LGG 10(11) CFU，持续四周。在给予益生菌前后，对粪便中的水、脂肪、氮和糖含量进行粪便近红外光谱分析（FENIR）。
5例患者（50%）出现细菌过度生长。我们发现氢试验与脂肪泻（R = 0.57）和粪便中的糖（R = 0.52）之间存在正相关。治疗前与治疗后的FENIR结果分别为：脂肪6.2 g +/- 3.3 g对4.9 g +/- 2.1 g（p < 0.05），糖6.7 +/- g 3.6 g对5 g +/- 2.6 g（p < 0.05），氮0.87 g +/- 0.27 g对0.91 g +/- 0.14 g（无统计学意义）。13例患者（81.25%）的粪便外观和肠道舒适度得到改善，9例患者（56.25%）的每日排便次数减少。
益生菌不仅改善了囊性纤维化患者的临床肠道功能，还改善了生化肠道功能。对于这类患者以及细菌过度生长的患者，可以将其作为常规治疗方法。
